U.S. markets closed

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
21.10-1.88 (-8.18%)
At close: 4:00PM EDT

21.00 -0.10 (-0.47%)
After hours: 7:59PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close22.98
Open22.70
Bid21.00 x 800
Ask21.55 x 900
Day's Range20.71 - 22.82
52 Week Range2.86 - 24.34
Volume751,224
Avg. Volume925,981
Market Cap2.7B
Beta (5Y Monthly)1.64
PE Ratio (TTM)131.88
EPS (TTM)0.16
Earnings DateMar 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-54% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021
    GlobeNewswire

    Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021

    CANTON, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2021 financial results will be reported after the market closes on Monday, May 10. Management will host a conference call at 5:00 p.m. Eastern Time on May 10 to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 9199306. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com. For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 9199306. The webcast will be archived at investors.organogenesis.com. About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com. CONTACT: Investor Inquiries: Westwicke Partners Mike Piccinino, CFA OrganoIR@westwicke.com Press and Media Inquiries: Organogenesis Lori Freedman lfreedman@organo.com

  • Organogenesis Holdings' (ORGO) Shares March Higher, Can It Continue?
    Zacks

    Organogenesis Holdings' (ORGO) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Organogenesis Holdings (ORGO).

  • Brokers Are Upgrading Their Views On Organogenesis Holdings Inc. (NASDAQ:ORGO) With These New Forecasts
    Simply Wall St.

    Brokers Are Upgrading Their Views On Organogenesis Holdings Inc. (NASDAQ:ORGO) With These New Forecasts

    Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shareholders will have a reason to smile today, with the analysts making...